Drug combo for older adults with progressive multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a combination of two existing drugs in people aged 55–85 with secondary progressive multiple sclerosis (SPMS). The goal is to see if the combo can slow down the disease. You need to have had SPMS for at least 12 months and not be on certain other MS treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged between 55 and 85 years old
- Diagnosed with secondary progressive multiple sclerosis (SPMS) for at least 12 months prior to the study
- Not treated with certain MS drugs (like alemtuzumab, cladribine, or mitoxantrone) within the last 6 months
- No recent heart problems, stroke, or hospitalization in the past 6 months
- No history of liver disease, Alzheimer's, or Parkinson's disease
- No current or recent drug or alcohol abuse or use of certain heart or psychiatric medications
- Must not be pregnant, breastfeeding, or planning to become pregnant during the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.
This early-phase study tests combination treatments for multiple sclerosis (MS) based on lab “biomarkers” found in the spinal fluid. It aims to reduce ongoing MS activity and help determine which treatment combinations may work best for different people.
This trial tests a new combination of drugs (isatuximab, bortezomib, lenalidomide, and dexamethasone) for people who are older or frail and have just been diagnosed with multiple myeloma. It aims to see if this treatment can help control the disease better, especially if certain cancer cells are found in the blood.
This trial tests whether adding two drugs, dasatinib and quercetin, to CAR-T therapy can help people with multiple myeloma that has come back or not responded to past treatments. It aims to make the CAR-T cells work better and reduce side effects.
This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.
This study tests a combination of two investigational drugs (Simmitinib and SG001) in people with advanced solid tumors that have not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth, and to find the best dose for further studies.
Hear when a new Multiple Sclerosis (MS) Secondary Progressive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.